Downregulation of O‑linked N‑acetylglucosamine transferase by RNA interference decreases MMP9 expression in human esophageal cancer cells

Qiao,Zhe; Dang,Chengxue; Zhou,Bin; Li,Shaomin; Zhang,Wei; Jiang,Jiantao; Zhang,Jin; Ma,Yuefeng; Kong,Ranran; Ma,Zhenchuan

doi:10.3892/ol.2016.4428

Downregulation of O‑linked N‑acetylglucosamine transferase by RNA interference decreases MMP9 expression in human esophageal cancer cells

Authors:
- Zhe Qiao
- Chengxue Dang
- Bin Zhou
- Shaomin Li
- Wei Zhang
- Jiantao Jiang
- Jin Zhang
- Yuefeng Ma
- Ranran Kong
- Zhenchuan Ma
View Affiliations

Affiliations: Department of Thoracic Surgery, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Surgical Oncology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: April 7, 2016 https://doi.org/10.3892/ol.2016.4428
Pages: 3317-3323
Copyright: © Qiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

O-linked N-acetylglucosamine transferase (OGT) catalyzes O-linked glycosylation (O-GlcNAcylation). O-GlcNAcylation is a post‑translational carbohydrate modification of diverse nuclear and cytosolic proteins by the addition of O‑linked β‑N‑acetylglucosamine. It was recently demonstrated that OGT and the level of O‑GlcNAcylation are upregulated in esophageal cancer; however, the physiological consequences of this upregulation remain unknown. The current study reports that OGT knockdown by short hairpin RNA (shRNA) did not affect cell viability; however, cell migration in esophageal cancer Eca‑109 cells was significantly reduced. OGT‑specific shRNA vectors efficiently decreased the protein and mRNA levels of OGT and the RL2 level (a marker of O‑GlcNAcylation levels) in Eca‑109 esophageal cancer cells. In addition, colony formation and cell proliferation assays demonstrated that OGT‑specific shRNA decreased the proliferation of Eca‑109 cells; however, there was no significant statistical difference between OGT‑specific shRNA and control shRNA. Notably, transwell assays demonstrated that the migratory ability of Eca‑109 cells was significantly suppressed following knockdown of the OGT gene. Correspondingly, western blot analyses demonstrated that OGT knockdown significantly downregulated the expression of matrix metalloproteinase 9 (MMP9) in Eca‑109 cells. These results suggest that OGT may promote the migration, invasion and metastasis of esophageal cancer cells by enhancing the stability or expression of MMP9.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Pakzad R, Mohammadian-Hafshejani A, Khosravi B, Soltani S, Pakzad I, Mohammadian M, Salehiniya H and Momenimovahed Z: The incidence and mortality of esophageal cancer and their relationship to development in Asia. Ann Transl Med. 4:292016.PubMed/NCBI
3	Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl 8): S4–S66. 2001. View Article : Google Scholar : PubMed/NCBI
4	van Rensburg SJ: Esophageal cancer, micronutrient malnutrition, and silica fragments. Lancet. 2:1098–1099. 1982. View Article : Google Scholar : PubMed/NCBI
5	National Comprehensive Cancer Network: NCCN Guidelines and Clinical Resources: Guidelines for Treatment of Cancer by Site. Version 7. 2015.
6	Brescia AA, Broderick SR, Crabtree TD, Puri V, Musick JF, Bell JM, Kreisel D, Krupnick AS, Patterson GA and Meyers BF: Adjuvant therapy for positive nodes after induction therapy and resection of esophageal cancer. Ann Thorac Surg. 101:200–210. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhang L, Ma J, Han Y, Liu J, Zhou W, Hong L and Fan D: Targeted therapy in esophageal cancer. Expert Rev Gastroenterol Hepatol. Feb 19–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
8	Zeidan Q and Hart GW: The intersections between O-GlcNAcylation and phosphorylation: Implications for multiple signaling pathways. J Cell Sci. 123:13–22. 2010. View Article : Google Scholar : PubMed/NCBI
9	Marshall S, Bacote V and Traxinger RR: Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 266:4706–4712. 1991.PubMed/NCBI
10	Copeland RJ, Bullen JW and Hart GW: Cross-talk between GlcNAcylation and phosphorylation: Roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab. 295:E17–E28. 2008. View Article : Google Scholar : PubMed/NCBI
11	Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, Puigserver P and Hart GW: O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem. 283:16283–16292. 2008. View Article : Google Scholar : PubMed/NCBI
12	Vosseller K, Wells L, Lane MD and Hart GW: Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA. 99:5313–5318. 2002. View Article : Google Scholar : PubMed/NCBI
13	Yang JY, Gu JL, Shi JH, Liu F and Shen Q: The inhibitory effect of OGT gene expression on the level of tau phosphorylation. Prog Biochem Biophys. 36:346–352. 2009. View Article : Google Scholar
14	Vervoorts J, Lüscher-Firzlaff J and Lüscher B: The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem. 281:34725–34729. 2006. View Article : Google Scholar : PubMed/NCBI
15	Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS and Cho JW: Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol. 8:1074–1083. 2006. View Article : Google Scholar : PubMed/NCBI
16	Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC and Brancati FL: Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. Jama. 300:2754–2764. 2008. View Article : Google Scholar : PubMed/NCBI
17	Torres CR and Hart GW: Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 259:3308–3317. 1984.PubMed/NCBI
18	Hart GW, Housley MP and Slawson C: Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 446:1017–1022. 2007. View Article : Google Scholar : PubMed/NCBI
19	Qiao Z, Dang C, Zhou B, Li S, Zhang W, Jiang J, Zhang J, Kong R and Ma Y: O-linked N-acetylglucosamine transferase (OGT) is overexpressed and promotes O-linked protein glycosylation in esophageal squamous cell carcinoma. J Biomed Res. 26:268–273. 2012. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Love DC and Hanover JA: The hexosamine signaling pathway: Deciphering the ‘O-GlcNAc code’. Sci STKE. 2005:re132005.PubMed/NCBI
22	Haltiwanger RS, Holt GD and Hart GW: Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine: Peptide beta-N-acetylglucosaminyltransferase. J Biol Chem. 265:2563–2568. 1990.PubMed/NCBI
23	Dong DL and Hart GW: Purification and characterization of an O-GlcNAc selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol. J Biol Chem. 269:19321–19330. 1994.PubMed/NCBI
24	Cetinbas N, Macauley MS, Stubbs KA, Drapala R and Vocadlo DJ: Identification of Asp174 and Asp175 as the key catalytic residues of human O-GlcNAcase by functional analysis of site-directed mutants. Biochemistry. 45:3835–3844. 2006. View Article : Google Scholar : PubMed/NCBI
25	Gao Y, Wells L, Comer FI, Parker GJ and Hart GW: Dynamic O-glycosylation of nuclear and cytosolic proteins: Cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem. 276:9838–9845. 2001. View Article : Google Scholar : PubMed/NCBI
26	Rogacka D, Piwkowska A, Jankowski M, Kocbuch K, Dominiczak MH, Stepiński JK and Angielski S: Expression of GFAT1 and OGT in podocytes: Transport of glucosamine and the implications for glucose uptake into these cells. J Cell Physiol. 225:577–584. 2010. View Article : Google Scholar : PubMed/NCBI
27	Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, Cong Q and Yu W: O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta. 1812:514–519. 2011. View Article : Google Scholar : PubMed/NCBI
28	Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, Vosseller K and Reginato MJ: Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene. 29:2831–2842. 2010. View Article : Google Scholar : PubMed/NCBI
29	Ngoh GA, Facundo HT, Zafir A and Jones SP: O-GlcNAc signaling in the cardiovascular system. Circ Res. 107:171–185. 2010. View Article : Google Scholar : PubMed/NCBI
30	Slawson C, Copeland RJ and Hart GW: O-GlcNAc signaling: A metabolic link between diabetes and cancer? Trends Biochem Sci. 35:547–555. 2010. View Article : Google Scholar : PubMed/NCBI
31	Gu Y, Mi W, Ge Y, Liu H, Fan Q, Han C, Yang J, Han F, Lu X and Yu W: GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res. 70:6344–6351. 2010. View Article : Google Scholar : PubMed/NCBI
32	Akter H, Park M, Kwon OS, Song EJ, Park WS and Kang MJ: Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol. 36:6053–6062. 2015. View Article : Google Scholar : PubMed/NCBI
33	Song J, Wu C, Korpos E, Zhang X, Agrawal SM, Wang Y, Faber C, Schäfers M, Körner H, Opdenakker G, et al: Focal MMP-2 and MMP-9 activity at the blood-brain barrier promotes chemokine-induced leukocyte migration. Cell Rep. 10:1040–1054. 2015. View Article : Google Scholar : PubMed/NCBI
34	Slawson C, Pidala J and Potter R: Increased N-acetyl-beta-glucosaminidase activity in primary breast carcinomas corresponds to a decrease in N-acetylglucosamine containing proteins. Biochim Biophys Acta. 1537:147–157. 2001. View Article : Google Scholar : PubMed/NCBI
35	Wang YZ, Wu JN, Sun RQ and Wu WX: Expression of MMP-9 and MMP-9 mRNA in esophageal carcinoma its correlation with antioncogene p53. Jiang Su Da Xue Xue Bao. 2:113–116. 2005.(In Chinese).
36	Kneass ZT and Marchase RB: Protein O-GlcNAc modulates motility-associated signaling intermediates in neutrophils. J Biol Chem. 280:14579–14585. 2005. View Article : Google Scholar : PubMed/NCBI
37	Hong S, Park KK, Magae J, Ando K, Lee TS, Kwon TK, Kwak JY, Kim CH and Chang YC: Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the erk1/2 signaling pathway: Inhibitory effects of ascochlorin on the invasion of renal carcinoma cells. J Biol Chem. 280:25202–25209. 2005. View Article : Google Scholar : PubMed/NCBI
38	Westermarck J and Kähäri VM: Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J. 13:781–792. 1999.PubMed/NCBI